 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CD38 |
| Clinical data | |
| Trade names | Sarclisa |
| Other names | SAR-650984, isatuximab-irfc |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a620023 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C6456H9932N1700O2026S44 |
| Molar mass | 145190.99 g·mol−1 |
Isatuximab, sold under the brand name Sarclisa, is a medication for the treatment of multiple myeloma.[3][2] It is used in people who have failed other treatments.[3] It is given by gradual injection into a vein.[2] It is often used together with dexamethasone and diphenhydramine.[3]
Common side effects include low neutrophils, infusion reactions, pneumonia, nose and throat infections, diarrhea, and bronchitis.[2] Other side effects may include anaphylaxis, and other types of cancer.[3] Use in pregnancy may harm the baby.[3] It is a monoclonal antibody (mAb) that attaches to CD38, which is commonly found on myeloma cells.[2]
Isatuximab was approved for medical use in the United States and Europe in 2020.[4][2] In the United Kingdom 500 mg cost the NHS about £2,500 as of 2021.[5] In the United States this amount costs about 3,600 USD.[6]
References
edit- ^ a b "Sarclisa Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 14 May 2020. Archived from the original on 10 October 2021. Retrieved 16 August 2020.
- ^ a b c d e f g "Sarclisa EPAR". European Medicines Agency (EMA). 24 March 2020. Archived from the original on 26 June 2020. Retrieved 25 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c d e f g "Sarclisa- isatuximab injection, solution, concentrate". DailyMed. 2 March 2020. Archived from the original on 16 October 2020. Retrieved 26 March 2020.
- ^ "Isatuximab-irfc Monograph for Professionals". Drugs.com. Archived from the original on 19 October 2021. Retrieved 26 November 2021.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 919. ISBN 978-0857114105.
- ^ "Sarclisa Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 28 November 2021.